World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://wjon.elmerpub.com

Original Article

Volume 16, Number 1, February 2025, pages 95-103

Impact of 2021 World Health Organization Grading, Peritumoral Edema, and Radiotherapy on the Recurrence of a Grossly Resected Intracranial Meningiomas: A Ten-Year Follow-Up Study

Figures

Figure 1.
Figure 1. Decision tree of the 124 patients enrolled in this study was segregated by sex, tumor location, WHO grading, treatment, and recurrence-free interval (RFI). WHO: World Health Organization; RT: radiotherapy.
Figure 2.
Figure 2. The relationship between WHO grading and RFI among all 124 patients with intracranial meningiomas. RFI: recurrence-free interval; WHO: World Health Organization.
Figure 3.
Figure 3. The relationship between peritumoral edema (PTE) and RFI among all 124 patients with intracranial meningiomas. RFI: recurrence-free interval.
Figure 4.
Figure 4. Peritumoral edema (PTE) around the intracranial meningioma. The left image is created using an artificial intelligence (AI) program, ChatGPT 4-DALL 2 plus.

Tables

Table 1. Characteristics of 124 Patients With Intracranial Meningioma
 
Overall (n = 124)
WHO: World Health Organization.
Age at diagnosis
  Mean (SD)49.0 (13.2)
  Range18.0 - 84.0
Sex
  Female87 (70.2%)
  Male37 (29.8%)
Tumor location
  Supratentorial110 (88.7%)
  Infratentorial14 (11.3%)
Presence of peritumoral edema (PTE)
  Present76 (61.3%)
  Not present48 (38.7%)
2021 WHO grading
  Grade I101 (81.5%)
  Grade II17 (13.7%)
  Grade III6 (4.8%)
Histological subtype
  Meningothelial93 (75.0%)
  Fibrous4 (3.2%)
  Angiomatous2 (1.6%)
  Secretory1 (0.8%)
  Microcystic1 (0.8%)
  Atypical16 (12.9%)
  Chordoid1 (0.8%)
  Anaplastic2 (1.6%)
  Rhabdoid4 (3.2%)
Post-surgical treatment
  Radiotherapy (RT)19 (15.3%)
Tumor recurrence
  No recurrence103 (83.1%)
  Recurrence21 (16.9%)
Survival status
  Survived118 (95.2%)
  Died6 (4.8%)

 

Table 2. The Relationship Between Patients’ Age, 2021 WHO Grading, and the Recurrence Rate Among 124 Meningioma Cases
 
No recurrence (n = 103, 83.1%)Recurrence (n = 21, 16.9%)Total (n = 124)P value
WHO: World Health Organization; SD: standard deviation.
Age at diagnosis, mean (SD)48.7 (13.3%)50.4 (12.8%)49.0 (13.2)0.594
WHO grading
  Grade I93 (90.3%)8 (38.1%)101 (81.5)< 0.001
  Grade II9 (8.7%)8 (38.1%)17 (13.7)
  Grade III1 (1.0%)5 (23.8%)6 (4.8)